A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT)

A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT)

BackgroundAdoptive cellular therapy (ACT) with genetically modified T cells aims to redirect T cells against resistant cancers through introduction of a T cell receptor (TCR). The Radium-4 TCR was isolated from a responding patient in a cancer vaccination study and recognizes the enzymatic component...

Full description

Bibliographic Details
Main Authors: Sólrún Melkorka Maggadóttir, Gunnar Kvalheim, Patrik Wernhoff, Stein Sæbøe-Larssen, Mona-Elisabeth Revheim, Dag Josefsen, Sébastien Wälchli, Åslaug Helland, Else Marit Inderberg
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Oncology
Subjects:
TCR immunotherapy
hTERT
NSCLC
mRNA electroporation
solid tumor immunotherapy
ACT
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1031232/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1031232/full

Similar Items